GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Toleranzia AB (OSTO:TOL) » Definitions » EV-to-FCF

Toleranzia AB (OSTO:TOL) EV-to-FCF : -1.55 (As of May. 12, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Toleranzia AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Toleranzia AB's Enterprise Value is kr88.57 Mil. Toleranzia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was kr-57.10 Mil. Therefore, Toleranzia AB's EV-to-FCF for today is -1.55.

The historical rank and industry rank for Toleranzia AB's EV-to-FCF or its related term are showing as below:

OSTO:TOL' s EV-to-FCF Range Over the Past 10 Years
Min: -41.45   Med: -0.95   Max: 3.84
Current: -1.55

During the past 10 years, the highest EV-to-FCF of Toleranzia AB was 3.84. The lowest was -41.45. And the median was -0.95.

OSTO:TOL's EV-to-FCF is ranked worse than
100% of 511 companies
in the Drug Manufacturers industry
Industry Median: 23.55 vs OSTO:TOL: -1.55

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Toleranzia AB's stock price is kr0.538. Toleranzia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.060. Therefore, Toleranzia AB's PE Ratio for today is At Loss.


Toleranzia AB EV-to-FCF Historical Data

The historical data trend for Toleranzia AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Toleranzia AB EV-to-FCF Chart

Toleranzia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.72 -2.61 -1.65 -2.14 -1.17

Toleranzia AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.14 -1.90 -1.79 -1.27 -1.17

Competitive Comparison of Toleranzia AB's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Toleranzia AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Toleranzia AB's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Toleranzia AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Toleranzia AB's EV-to-FCF falls into.



Toleranzia AB EV-to-FCF Calculation

Toleranzia AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=88.570/-57.101
=-1.55

Toleranzia AB's current Enterprise Value is kr88.57 Mil.
Toleranzia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-57.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Toleranzia AB  (OSTO:TOL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Toleranzia AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.538/-0.060
=At Loss

Toleranzia AB's share price for today is kr0.538.
Toleranzia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.060.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Toleranzia AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Toleranzia AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Toleranzia AB (OSTO:TOL) Business Description

Traded in Other Exchanges
N/A
Address
Erik Dahlbergsgatan 11A, Gothenburg, SWE, SE-411 26
Toleranzia AB is a pharmaceutical company based in Sweden. The company's drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an orphan disease.